Researchers present scoring system for lung cancer screening

Share this content:

the ONA take:

LungRADS, a system for scoring lung lesions seen in screening studies, was reviewed during a HotTopics session at the meeting of the Radiological Society of North America. The hope is for LungRADS to work as effectively for lung cancer as BI-RADS works for breast cancer. The new tool uses the same scale to classify lesions into categories such as Incomplete (Category 0), Negative (Category 1), Benign appearance or behavior (Category 2), Probably benign (Category 3), and Suspicious (Category 4A and 4B). LungRADS also describes how nodule size, nodule consistency, benign and benign behavior versus active cancer can further identify potentially dangerous lesions, perhaps reducing the number of false positive findings. In the National Lung Screening Trial (NLST), 40% of participants received at least one false positive result over 3 years; 1.4% of those patients who underwent a diagnostic procedure as a result of a positive result experienced a complication. Reducing false positive results on screening is critical. Using this tool may reduce the false positive findings from 1 in 4 cases, as seen in the NLST, to 1 in 10 cases.

Researchers present scoring system for lung cancer screening
Researchers present scoring system for lung cancer screening
CHICAGO -- A system of scoring lung lesions observed in screening studies was reviewed here by researchers for the American College of Radiology (ACR) who hope the new tool will be as successful for lung cancer screening as ACR's BI-RADS has been for breast cancer.
READ FULL ARTICLE From Medical Page Today
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs